Takeda bags Japanese approval for Crohn’s cell therapy AlofiselTakeda has chalked up another milestone for its Alofisel cell therapy for a complication of Crohn’s disease, becoming Share XTakeda bags Japanese approval for Crohn’s cell therapy Alofiselhttps://pharmaphorum.com/news/takeda-bags-japanese-approval-for-crohns-cell-therapy-alofisel/
Daiichi Sankyo claims first okay for oncolytic virus in JapanDaiichi Sankyo has made a little bit of pharma industry history, becoming the first drugmaker to win approval Share XDaiichi Sankyo claims first okay for oncolytic virus in Japanhttps://pharmaphorum.com/news/daiichi-sankyo-claims-first-okay-for-cancer-killing-virus-in-japan/
Novo Nordisk crowns cell therapy pipeline with $598m Heartseed dealNovo Nordisk is paying $55 million upfront to secure rights to a cell therapy for heart failure developed Share XNovo Nordisk crowns cell therapy pipeline with $598m Heartseed dealhttps://pharmaphorum.com/news/novo-nordisk-crowns-cell-therapy-pipeline-with-598m-heartseed-deal/
Chasing Merck, Eisai launches insomnia drug Dayvigo in JapanEisai has launched its insomnia drug Dayvigo in Japan, the second in a new class of medicines after Share XChasing Merck, Eisai launches insomnia drug Dayvigo in Japanhttps://pharmaphorum.com/news/chasing-merck-eisai-launches-insomnia-drug-dayvigo-in-japan/
The Japanese healthcare revolutionSomething that always strikes me when visiting Japan is the uber-modern infrastructure and services enjoyed by residents and Share XThe Japanese healthcare revolutionhttps://pharmaphorum.com/views-analysis-oncology/the-japanese-healthcare-revolution/
Trial sets up 2020 filing for Poxel’s novel diabetes drugFrench biotech Poxel has positive phase 3 data for a new type of oral therapy for type 2 Share XTrial sets up 2020 filing for Poxel’s novel diabetes drughttps://pharmaphorum.com/news/trial-sets-up-2020-filing-for-poxels-novel-diabetes-drug/
Promethera looks to Asia with €10m investmentBelgium-based liver disease specialists Promethera Biosciences have received a leg-up for the Asian market in the form of Share XPromethera looks to Asia with €10m investmenthttps://pharmaphorum.com/news/promethera-looks-to-asia-with-e10m-investment/
AstraZeneca gets further approval for Tagrisso in JapanAstraZeneca received approval from the Japanese regulator following a priority review of Tagrisso (osimertinib) as a first-line treatment Share XAstraZeneca gets further approval for Tagrisso in Japanhttps://pharmaphorum.com/news/astrazeneca-tagrisso-approval/
AstraZeneca cancer drugs approved in JapanAstraZeneca secured a fast approval of lung and breast cancer drugs with usually sluggish Japanese regulators, just months Share XAstraZeneca cancer drugs approved in Japanhttps://pharmaphorum.com/r-d/astrazenecas-cancer-drugs-approved-japan/
